v3.26.1
Significant Accounting Policies and Estimates (Tables)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents
   June 30,   June 30, 
   2026   2025 
Cash  $492   $725 
Restricted cash   1,214    - 
Total cash and restricted cash shown in the statement of cash flows  $1,706   $725 
Schedule of Fair Value of Derivative Liabilities

   Level 1   Level 2   Level 3   Total 
Derivative liability as of June 30, 2026 ($ in thousands)  $   $   $8,665   $8,665 
Schedule of Level 3 Roll-forward for Derivative Liabilities

Level 3 Roll-forward

 

   Amount ($ in thousands) 
Balance at January 1, 2026  $ 
Initial recognition of derivative liability   10,101 
Changes in fair value   (1,436)
Balance at June 30, 2026  $8,665 

Schedule of Disaggregated Revenue by Sales Type

Disaggregated revenue by sales type ($ in thousands):

   2026   2025 
   Three Months Ended 
   June 30, 
   2026   2025 
Contract manufacturing  $1,038   $863 
Custom and white label finished goods manufacturing   -    27 
Consumer branded products   1,756    1,884 
Medical devices/other   78    110 
Biomaterial products   814    - 
Total  $3,686   $2,884 

 

   2026   2025 
   Six Months Ended 
   June 30, 
   2026   2025 
Contract manufacturing  $1,954   $1,811 
Custom and white label finished goods manufacturing   -    27 
Consumer branded products   3,377    3,666 
Medical devices/other   191    186 
Biomaterial products   814    - 
Total  $6,336   $5,690